GlassScriptPhysician profile
Cheryl L Eldridge
NPI 1336246438
$2,399.81
in general payments reported to CMS, 2019-2025
23 companies · $1,336 in 2025
The $1,336 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $646 · 2024: $418 · 2025: $1,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,335 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,335.27 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $812.06 | 2025 | Rapiblyk |
| Amgen INC. | $284.77 | 2023-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $174.37 | 2023-2024 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.63 | 2023-2025 | Jardiance |
| Abbott Laboratories | $139.00 | 2024 | Cardiomems |
| Bayer Healthcare Pharmaceuticals INC. | $96.37 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $95.84 | 2024-2025 | Lifevest |
| Novo Nordisk INC | $82.51 | 2024 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $77.75 | 2023 | |
| Janssen Pharmaceuticals, INC | $62.78 | 2023-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $60.80 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $50.89 | 2023-2025 | Verquvo, Winrevair |
| Boston Scientific Corporation | $45.11 | 2025 | Watchman Flx |
| Heartflow, INC. | $44.74 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $39.34 | 2025 | Evkeeza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $33.78 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $22.74 | 2023 | Farxiga |
| Kiniksa Pharmaceuticals International, Plc | $21.79 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $21.52 | 2023 | Arcalyst |
| Atricure, INC. | $20.68 | 2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Actelion Pharmaceuticals US, INC. | $19.59 | 2023 | Uptravi, Opsumit |
| Sanofi-Aventis U.S. LLC | $16.00 | 2023 | |
| Lilly USA, LLC | $14.75 | 2025 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Eldridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.